BRCA mutations detected by tumour next-generation sequencing in non-small cell lung cancer: impact on response to therapy and disease course

被引:2
作者
Tschernichovsky, Roi [1 ]
Averbuch, Itamar [1 ]
Goldstein, Daniel Alex [2 ]
Mutai, Raz [3 ]
Dudnik, Elizabeth [4 ]
Rotem, Ofer [3 ]
Laufer-Geva, Smadar [5 ]
Peled, Nir [6 ]
Goldberg, Yael [7 ]
Zer, Alona [8 ]
机构
[1] Sackler Fac Med, Radiat Oncol Unit, Davidoff Ctr, Rabin Med Ctr, Petah Tiqwa, Israel
[2] Sackler Fac Med, Genito Urinary Canc Unit, Davidoff Ctr, Rabin Med Ctr, Petah Tiqwa, Israel
[3] Sackler Fac Med, Thorac Canc Unit, Davidoff Ctr, Rabin Med Ctr, Petah Tiqwa, Israel
[4] Assuta Ashdod Univ Hosp, Div Oncol, Ashdod, Israel
[5] Edmond & Lily Safra Childrens Hosp, Sheba Med Ctr, Sackler Fac Med, Ramat Gan, Israel
[6] Shaare Zedek Med Ctr, Oncol Inst, Jerusalem, Israel
[7] Sackler Fac Med, Raphael Recanati Genet Inst, Rabin Med Ctr, Petah Tiqwa, Israel
[8] Rambam Hlth Care Campus, Fishman Oncol Inst, Haifa, Israel
关键词
Non-small cell lung cancer (NSCLC); BRCA; chemo-immunotherapy; next-generation sequencing (NGS); platinum-based therapy; METASTATIC BREAST-CANCER; PROSTATE-CANCER; ASSOCIATION; OLAPARIB; RATES; PEMBROLIZUMAB; PREVALENCE; WOMEN;
D O I
10.21037/tlcr-22-594
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Data regarding the prevalence and clinical relevance of BRCA mutations in non-small cell lung cancer (NSCLC) is limited. Our objective was to evaluate the impact of pathogenic BRCA variants detected by tumour next-generation sequencing (NGS) on disease course and response to therapy. Methods: We performed a retrospective analysis of all consecutive NSCLC patients with available NGS reports in a single institution between 01/2015 and 08/2020. Pathogenicity of identified mutations was determined according to American College of Medical Genetics (ACMG) guidelines. Log rank and cox regression analyses were used to determine the association between BRCA mutation status, overall survival (OS) and progression-free survival (PFS) under various front-line treatment modalities for advanced disease. Results: Out of 445 patients with NGS data (54% tissue, 46% liquid), 109 (24.5%) patients had a documented BRCA variant; 5.6% (25/445) had a pathogenic/likely pathogenic variant (pBRCA). Forty percent (10/25) of pBRCA patients had no co-occurring NSCLC driver mutations. Patients with pBRCA NSCLC had a less prominent smoking history [mean 42.6 (29.2) vs. 25.7 (24.0) pack years; P=0.024]. Median PFS with first-line chemo-immunotherapy was significantly prolonged for pBRCA patients (n=7) compared with wild-type BRCA (wtBRCA) patients (n=30) (HR =0.279; P=0.021, 95% CI: 0.094-0.825). Conclusions: pBRCA-mutated NSCLC can represent a specific subtype of pulmonary carcinoma. Patients whose tumours harbor pBRCA mutations present with a less prominent smoking history and exhibit prolonged PFS with chemo-immunotherapy combinations compared with wtBRCA controls. In a subset of these patients, pBRCA is the sole identifiable putative driver mutation, hinting at a significant role for BRCA loss in oncogenesis.
引用
收藏
页码:1011 / +
页数:15
相关论文
共 32 条
[1]  
Adams S, 2019, ANN ONCOL, V30, P405, DOI [10.1093/annonc/mdy518, 10.1093/annonc/mdy517]
[2]   Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study [J].
Dirix, Luc Y. ;
Takacs, Istvan ;
Jerusalem, Guy ;
Nikolinakos, Petros ;
Arkenau, Hendrik-Tobias ;
Forero-Torres, Andres ;
Boccia, Ralph ;
Lippman, Marc E. ;
Somer, Robert ;
Smakal, Martin ;
Emens, Leisha A. ;
Hrinczenko, Borys ;
Edenfield, William ;
Gurtler, Jayne ;
von Heydebreck, Anja ;
Grote, Hans Juergen ;
Chin, Kevin ;
Hamilton, Erika P. .
BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (03) :671-686
[3]   Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer [J].
Gadgeel, Shirish ;
Rodriguez-Abreu, Delvys ;
Speranza, Giovanna ;
Esteban, Emilio ;
Felip, Enriqueta ;
Domine, Manuel ;
Hui, Rina ;
Hochmair, Maximilian J. ;
Clingan, Philip ;
Powell, Steven F. ;
Cheng, Susanna Yee-Shan ;
Bischoff, Helge G. ;
Peled, Nir ;
Grossi, Francesco ;
Jennens, Ross R. ;
Reck, Martin ;
Garon, Edward B. ;
Novello, Silvia ;
Rubio-Viqueira, Belen ;
Boyer, Michael ;
Kurata, Takayasu ;
Gray, Jhanelle E. ;
Yang, Jing ;
Bas, Tuba ;
Pietanza, M. Catherine ;
Garassino, Marina C. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (14) :1505-+
[4]   Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer [J].
Gershoni-Baruch, R ;
Dagan, E ;
Fried, G ;
Bar-Sade, RB ;
Sverdlov-Shiri, R ;
Zelicksson, G ;
Friedman, E .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (08) :983-986
[5]   Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer [J].
Golan, Talia ;
Hammel, Pascal ;
Reni, Michele ;
Van Cutsem, Eric ;
Macarulla, Teresa ;
Hall, Michael J. ;
Park, Joon-Oh ;
Hochhauser, Daniel ;
Arnold, Dirk ;
Oh, Do-Youn ;
Reinacher-Schick, Anke ;
Tortora, Giampaolo ;
Alguel, Hana ;
O'Reilly, Eileen M. ;
McGuinness, David ;
Cui, Karen Y. ;
Schlienger, Katia ;
Locker, Gershon Y. ;
Kindler, Hedy L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04) :317-327
[6]   BRCA2 germline mutations in familial pancreatic carcinoma [J].
Hahn, SA ;
Greenhalf, B ;
Ellis, I ;
Sina-Frey, M ;
Rieder, H ;
Korte, B ;
Gerdes, B ;
Kress, R ;
Ziegler, A ;
Raeburn, JA ;
Campra, D ;
Grützmann, R ;
Rehder, H ;
Rothmund, M ;
Schmiegel, W ;
Neoptolemos, JP ;
Bartsch, DK .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (03) :214-221
[7]   Cancer surveillance series: Interpreting trends in prostate cancer - Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates [J].
Hankey, BF ;
Feuer, EJ ;
Clegg, LX ;
Hayes, RB ;
Legler, JM ;
Prorok, PC ;
Ries, LA ;
Merrill, RM ;
Kaplan, RS .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (12) :1017-1024
[8]   Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients [J].
Hu, Xingsheng ;
Yang, Dongyong ;
Li, Yalun ;
Li, Li ;
Wang, Yan ;
Chen, Peng ;
Xu, Song ;
Pu, Xingxiang ;
Zhu, Wei ;
Deng, Pengbo ;
Yen, Junyi ;
Zhang, Hanhan ;
Lizaso, Analyn ;
Liu, Hao ;
Mao, Xinru ;
Huang, Hai ;
Chu, Qian ;
Hu, Chengping .
CANCER BIOLOGY & MEDICINE, 2019, 16 (03) :556-564
[9]   Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies [J].
Jordan, Emmet J. ;
Kim, Hyunjae R. ;
Arcila, Maria E. ;
Barron, David ;
Chakravarty, Debyani ;
Gao, JianJiong ;
Chang, Matthew T. ;
Ni, Andy ;
Kundra, Ritika ;
Jonsson, Philip ;
Jayakumaran, Gowtham ;
Gao, Sizhi Paul ;
Johnsen, Hannah C. ;
Hanrahan, Aphrothiti J. ;
Zehir, Ahmet ;
Rekhtman, Natasha ;
Ginsberg, Michelle S. ;
Li, Bob T. ;
Yu, Helena A. ;
Paik, Paul K. ;
Drilon, Alexander ;
Hellmann, Matthew D. ;
Reales, Dalicia N. ;
Benayed, Ryma ;
Rusch, Valerie W. ;
Kris, Mark G. ;
Chaft, Jamie E. ;
Baselga, Jose ;
Taylor, Barry S. ;
Schultz, Nikolaus ;
Rudin, Charles M. ;
Hyman, David M. ;
Berger, Michael F. ;
Solit, David B. ;
Ladanyi, Marc ;
Riely, Gregory J. .
CANCER DISCOVERY, 2017, 7 (06) :596-609
[10]   Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization [J].
Kadouri, Luna ;
Rottenberg, Yakir ;
Zick, Aviad ;
Hamburger, Tamar ;
Lipson, Doron ;
Peretz, Tamar ;
Nechushtan, Hovav .
LUNG CANCER, 2019, 137 :48-51